Last reviewed · How we verify
Skelid (TILUDRONIC ACID)
At a glance
| Generic name | TILUDRONIC ACID |
|---|---|
| Drug class | Bisphosphonate |
| Target | 72 kDa type IV collagenase |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Osteitis deformans
Common side effects
Key clinical trials
- Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use
- Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Skelid CI brief — competitive landscape report
- Skelid updates RSS · CI watch RSS